Quel avenir pour les nouvelles thérapeutiques ?

Abstract

A certain number of new potential therapies for hereditary angioedema (HAE) are currently being studied. They include new inhibitors of the contact system, such as ecallantide, a kallikrein inhibitor, Icatibant, a bradykinin receptor B2 antagonist, as well as a recombinant C1-INH secreted in the milk of transgenic rabbits. Publication of the data concerning these state-of-the-art therapies could be the beginning of new therapeutic advances in the treatment of HAE and, hopefully, lead to reduction in the burden that this condition represents.